As I understand it, the raw hide comes from tissue banks, which, by law, are non-profits. Back when sales projections were far higher, a former VP in charge of IR told me on several occasions they anticipated no difficulties in securing adequate supplies of cadaver skin for the foreseeable future.
Seems it was the fall of '95 when the FDA rated Alloderm as banked human tissue, which is not subject to the same level of scrutiny as artificial products. That could change. My guess is that intense editorial commentary on the arbitrary, perhaps tyrannical nature of the FDA in years prior will tend to preclude shifts without adequate cause.
As you note, sales, thus earnings estimates, have been cut dramatically from projections in the past. Based on some years of following LIFC, let me give you an unequivocal opinion on when they will turn profitable:
-
-
-
Someday,
-
-
-
-
-
maybe.
Good luck. |
